Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Shareholders Approve Genoptix Merger

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that its shareholders have approved its proposed merger with Genoptix.

Late last year, Genoptix agreed to acquire Rosetta for $10 million in cash, but the deal was scuttled after failing to garner enough support from Rosetta shareholders. Several months later, the companies signed a new merger agreement that valued Rosetta at $9 million.

Rosetta said that its shareholders have approved the latest agreement and that the merger is now slated to close on May 27. Following completion of the deal, Rosetta will become a privately held subsidiary of Genoptix, and its shares will cease to trade on the Nasdaq.

During midday trading, shares of Rosetta were down less than 1 percent to $.43.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.